TenNor Therapeutics (Suzhou) Limited (Ticker: 6872 HK) is a China-domiciled biotechnology company developing therapies for bacterial infections and diseases associated with bacterial metabolism. The company’s pipeline includes seven programs, including rifasutenizol (TNP-2198), which is being developed for H. pylori infection, bacterial vaginosis and C. difficile infection, and rifaquizinone (TNP-2092 injection), which is being developed for implant-associated bacterial infections and bloodstream-related infections.

TenNor Therapeutics is expected to list H shares on the Hong Kong Stock Exchange Main Board on May 22, 2026. According to published terms, the company is offering 8.28 million shares at HKD 75.70 per share, raising approximately HKD 627 million, or about $80 million. The market capitalization at the offer price is approximately $500 million.

The IPO consists entirely of primary shares and includes a 15% greenshoe option. According to the prospectus, the company plans to use the proceeds for R&D and product capacity, brand promotion and business development, working capital, and strategic acquisitions. CITIC Securities (Hong Kong) and ABCI Capital are sponsors of the offering.